Literature DB >> 8555712

Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria.

P Griffiths1, L Paterson, A Harvie.   

Abstract

Severe mental handicap in phenylketonuria (PKU) can be prevented if dietary treatment is implemented at birth. Controversy remains about the optimum age for terminating treatment. A group of adolescents and young adults with PKU from the West of Scotland Register was identified which had received early treatment, been well-controlled on diet, ceased treatment at 10 years old and subsequently were hyperphenylalaninaemic for 3 years or more. They were given a battery of neuropsychological tests and their results were compared with those of on-diet subjects with PKU and normal controls. The findings generally supported the view that dietary cessation at age 10 is sufficient to prevent a substantial reduction of cognitive and motor ability, and that the central nervous system is probably mature enough to withstand the toxic effects of high blood phenylalanine by then. However, there were minor indications, in keeping with Welsh et al.'s hypothesis [M.C. Welsh, B.F. Pennington, S. Ozonoff, B. Rouse & E.R.B. McCabe (1990) Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8555712     DOI: 10.1111/j.1365-2788.1995.tb00540.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  13 in total

1.  Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test.

Authors:  P Griffiths; R Campbell; P Robinson
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

2.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

3.  Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria.

Authors:  P Griffiths; N Ward; A Harvie; F Cockburn
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

Review 4.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

5.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

Review 6.  Mild hyperphenylalaninemia: to treat or not to treat.

Authors:  Francjan J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

7.  Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

Authors:  R Matalon; K Michals-Matalon; G Bhatia; A B Burlina; A P Burlina; C Braga; L Fiori; M Giovannini; E Grechanina; P Novikov; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2007-02-27       Impact factor: 4.750

Review 8.  Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria.

Authors:  Deborah A Bilder; J Kay Noel; Erin R Baker; William Irish; Yinpu Chen; Markus J Merilainen; Suyash Prasad; Barbara J Winslow
Journal:  Dev Neuropsychol       Date:  2016-11-02       Impact factor: 2.253

9.  Cognitive outcomes in early-treated adults with phenylketonuria (PKU): A comprehensive picture across domains.

Authors:  Liana Palermo; Tarekegn Geberhiwot; Anita MacDonald; Ellie Limback; S Kate Hall; Cristina Romani
Journal:  Neuropsychology       Date:  2017-01-12       Impact factor: 3.295

10.  Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.

Authors:  D Concolino; I Mascaro; M T Moricca; G Bonapace; K Matalon; J Trapasso; G Radhakrishnan; C Ferrara; R Matalon; P Strisciuglio
Journal:  Eur J Clin Nutr       Date:  2016-09-14       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.